Technical analysis of Avalo Therapeutics, Inc. (AVTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
Price Performance
| 1 month | -15.88% |
| 3 months | +12.79% |
| Year-to-date | -8.70% |
| 1 year | +46.34% |
| 3 years | -43.83% |
| 5 years | -99.77% |
52-Week Range
| 52-week High | $24.27 |
| 52-week Low | $9.54 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $18.88 |
| SMA 200 | $16.89 |
| Beta | 0.94 |
| 30-day Volatility (annualised) | 52.4% |
| Price vs SMA 50 | -12.2% |
| Price vs SMA 200 | -1.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $18.03 | |
| 2025-11 | $19.00 | +5.4% |
| 2025-12 | $18.16 | -4.4% |
| 2026-01 | $15.11 | -16.8% |
| 2026-02 | $17.50 | +15.8% |
| 2026-03 | $14.93 | -14.7% |
| 2026-04 | $13.40 | -10.2% |
| 2026-05 | $15.95 | +19.0% |
| 2026-06 | $18.48 | +15.9% |
| 2026-07 | $18.25 | -1.2% |
| 2026-08 | $19.34 | +6.0% |
| 2026-09 | $16.58 | -14.3% |
Price
| Price | $16.58 |
| Market Cap | $872M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.61 |
| EV / EBITDA | -9.25 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 19.31 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -2.13 |